CLAIMS

[Claim 1]
An agent for maintaining or improving a cerebral function, comprising an herbal medicine selected from māmaki leaves, fruit, and seeds.

[Claim 2]
The agent for maintaining or improving a cerebral function according to claim 1, wherein the cerebral function is cognitive function.

[Claim 3]
An agent for promoting nerve cell repair or inducing neurogenesis, comprising an herbal medicine selected from māmaki leaves, fruit, and seeds.

[Claim 4]
An agent for removing a neurodegenerative disease-causing protein that accumulates in the brain, comprising an herbal medicine selected from māmaki leaves, fruit, and seeds.

[Claim 5]
The agent according to claim 4, wherein the neurodegenerative disease-causing protein is one or more proteins selected from amyloid β (Aβ), tau, α-synuclein, TDP-43, FUS/TLS, polyglutamine, a protein resulting from RAN (repeat-associated non-ATG) translation, prion, and SOD-1.

[Claim 6]
An agent for treating or preventing a neurodegenerative disease, comprising an herbal medicine selected from māmaki leaves, fruit, and seeds.

[Claim 7]
The agent according to claim 6, wherein the neurodegenerative disease is degenerative dementia.

[Claim 8]
The agent according to claim 7, wherein the degenerative dementia is one or more dementias selected from Alzheimer's disease, frontotemporal dementia, Lewy body dementia, and dementia resulting from Parkinson's disease or amyotrophic lateral sclerosis.

[Claim 9]
The agent according to any one of claims 1 to 8, wherein the herbal medicine selected from māmaki leaves, fruit, and seeds is a crushed product and/or an extract of māmaki leaves and/or fruit and/or seeds.

[Claim 10]
The agent according to any one of claims 1 to 9, wherein the herbal medicine is to be administered to a subject at an amount of from 0.01 mg to 10 g per day.

[Claim 11]
A food product comprising the agent according to any one of claims 1 to 10.

[Claim 12]
A pharmaceutical product comprising the agent according to any one of claims 1 to 10.

[Claim 13]
A non-therapeutic use of a crushed product and/or an extract of māmaki leaves and/or fruit and/or seeds for maintaining or improving a cerebral function in a subject.

[Claim 14]
The non-therapeutic use according to claim 13, wherein the cerebral function is cognitive function.

[Claim 15]
A non-therapeutic use of a crushed product and/or an extract of māmaki leaves and/or fruit and/or seeds for promoting nerve cell repair or inducing neurogenesis in a subject.

[Claim 16]
Use of the pharmaceutical product according to claim 12 in the manufacture of a medicament for treating a neurodegenerative disease in a subject, wherein the medicament removes a neurodegenerative disease-causing protein that accumulates in the brain of the subject.

[Claim 17]
The use according to claim 16, wherein the neurodegenerative disease-causing protein is one or more proteins selected from amyloid β (Aβ), tau, α-synuclein, TDP-43, FUS/TLS, polyglutamine, a protein resulting from RAN (repeat-associated non-ATG) translation, prion, and SOD-1.

[Claim 18]
Use of the pharmaceutical product according to claim 12 in the manufacture of a medicament for treating or preventing a neurodegenerative disease in a subject.

[Claim 19]
The use according to claim 18, wherein the neurodegenerative disease is degenerative dementia.

[Claim 20]
The use according to claim 19, wherein the degenerative dementia is one or more dementias selected from Alzheimer's disease, frontotemporal dementia, Lewy body dementia, and dementia resulting from Parkinson's disease or amyotrophic lateral sclerosis.

[Claim 21]
The use according to any one of claims 16 to 20, wherein the medicament comprises a crushed product and/or an extract of māmaki leaves and/or fruit and/or seeds.

[Claim 22]
The use according to any one of claims 16 to 21, wherein the medicament is to be administered to the subject at an amount of from 0.01 mg to 10 g per day.

[Claim 23]
The pharmaceutical product according to claim 12 for use in therapy.